nifurtimox


Also found in: Dictionary, Wikipedia.
Related to nifurtimox: Eflornithine

nifurtimox

A drug used in the treatment of South American trypanosomiasis (CHAGAS' DISEASE). The drug is effective against the causal agent Trypanosoma cruzi but its use is associated with side effects such as nausea, vomiting, loss of appetite, abdominal pain, muscle and joint aches, headache and vertigo. The drug is on the WHO official list.

nifurtimox

a nitrofuran derivative used as an antitrypanosomal agent.
References in periodicals archive ?
Introduced in the 1960s and 1970s nifurtimox (Nx) and benznidazole (Bz), two nitroheterocyclic drugs, are currently used for treatment of Chagas disease although their availability is limited and are not approved by the FDA.
Two drugs are currently used: nifurtimox and benzonidazole.
The currently available treatment of infected patients is limited because the only drugs available, nifurtimox (Lampit) and benznidazole (Radanil, Rochagan), have limited efficacy and present systemic toxicity that causes several side effects (Maya et al.
Nifurtimox or benznidazole are used for treatment, although neither drug is approved by the Food and Drug Administration.
Nifurtimox and benznidazole are the only antichagasic drugs with clinical efficacy, but they are far from optimal because of collateral effects.
ATLANTA -- The approval of the cosmetic formulation of eflornithine encouraged the reintroductions of its intravenous formulation and of nifurtimox, both used to treat African trypanosomiasis, Dr.
The only available medicines for treatment are benznidazole and nifurtimox, which treat the acute phase and have poor patient compliance due to various side effects.
The newborn received nifurtimox (10 mg/kg/d for 60 days) without notable adverse effects.
The drugs currently in use against this disease, nifurtimox and benznidazole, present several side effects and have limited efficacy (Kirchhoff, 2003).
The severe side-effects of benznidazole and nifurtimox, including agranulocytosis, hypersensibility reactions and anorexia, make them poorly tolerated (Almeida and Gazzinelli, 2001).
Nifurtimox was given (and was well tolerated) after the patient's cutaneous and blood status had normalized.